Are there differences between vasodilating and nonvasodilating beta-blockers in patients with heart failure? Do patients with ischemic heart disease benefit to the same degree?
Dickerson
L M
LM
Medical University of South Carolina, Charleston, USA. macfarll@musc.edu
Carek
P J
PJ
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D005260:Female; D006333:Heart Failure / Q000209:etiology* / Q000401:mortality; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008790:Metoprolol / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000150:complications; D011412:Propanolamines / Q000627:therapeutic use*; D015203:Reproducibility of Results; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D014665:Vasodilator Agents; D000077261:Carvedilol; D008790:Metoprolol